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Abstract
Background: Central nervous system (CNS) spreading from epithelial ovarian carcinoma (EOC) is an uncommon
but increasing phenomenon. We previously reported in a small series of 11 patients a correlation between
Androgen Receptor (AR) loss and localization to CNS. Aims of this study were: to confirm a predictive role of AR
loss in an independent validation cohort; to evaluate if AR status impacts on EOC survival.
Results: We collected an additional 29 cases and 19 controls as validation cohort. In this independent cohort at
univariate analysis, cases exhibited lower expression of AR, considered both as continuous (p < 0.001) and as
discrete variable (10% cut-off: p < 0.003; Immunoreactive score: p < 0.001). AR negative EOC showed an odds ratio
(OR) = 8.33 for CNS dissemination compared with AR positive EOC. Kaplan-Meier curves of the combined dataset,
combining data of new validation cohort with the previously published cohort, showed that AR < 10% significantly
correlates with worse outcomes (p = 0.005 for Progression Free Survival (PFS) and p = 0.002 for brain PFS (bPFS)
respectively).
Comparison of AR expression between primary tissue and paired brain metastases in the combined dataset did not
show any statistically significant difference.
Conclusions: We confirmed AR loss as predictive role for CNS involvement from EOC in an independent cohort of
cases and controls. Early assessment of AR status could improve clinical management and patients’ prognosis.
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Background
Epithelial ovarian cancer (EOC) is the third cause of
death among gynaecological malignancies worldwide [1].
Peritoneal cavity is the most common EOC site of pro-
gression, but haematogenous spreading may occur too
[2], involving liver, distant lymph nodes, pleura, lungs
and, less frequently, skin and bone [3, 4]. Central ner-
vous system (CNS) is a rare localization of disease, with
a reported incidence ranging between 0,3 and 12% [4, 5].
Recently, brain involvement seems to increase [6], prob-
ably due to improvement of medical treatments, radio-
therapy and surgery [3, 7–10]. Negative prognostic
factors in patients with CNS involvement are extra-
cranial disease, single-treatment approach, multiple
brain lesions, low Karnofsky Performance Status, non-
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serous histology, older age at diagnosis [7–10] and non-
surgical treatment [11]. Median overall survival (OS) is
about 5 months for women undergoing a single-modality
treatment versus 22 months if a multimodal approach is
pursued [10, 11].
Unfortunately, no predictive biomarkers of CNS in-
volvement have been validated in EOC at present.
Considering its already known negative prognostic
value, we focused our interest on Androgen Receptor
(AR) [12, 13]. Interestingly, in our previously published
small series of 11 patients, AR-negativity predicted a 9.5
times higher propensity of CNS involvement [14].
Aims of the present study were: i) to confirm AR’s
predictive role for CNS dissemination from EOC in an
independent validation cohort, and ii) to assess the role
of AR expression in terms of progression free survival
(PFS) and brain progression free survival (bPFS) in the
combined dataset.
Methods
Patients’ validation cohort collection
In order to validate AR’s predictive role of CNS involve-
ment form EOC, we extended our previously published
series of eleven patients [14]. Fourteen new cases with
paired brain lesions and 15 new cases with CNS involve-
ment not surgically removed, diagnosed from April 2000
to December 2015, were added. These cases were ob-
tained from the Pathology archives of Hospitals with
recognized expertise in treatment of EOC, members of
the Neuro-Oncological Network of the Piedmont Region
(Italy) (AOU Città della Salute e della Scienza of Turin,
AO San Giovanni Bosco Hospital of Turin, AOU Mag-
giore della Carità of Novara, AO S. Croce e Carle Hos-
pital of Cuneo, AO SS. Antonio, Biagio e Cesare Arrigo
of Alessandria, ASL CN2 Hospitals of Alba and Bra, AO
Martini, Hospital of Turin, AO Maria Vittoria, Hospital
of Turin, AO Mauriziano, Hospital of Turin),and from
Azienda Socio Sanitaria Territoriale (ASST) Spedali
Civili of Brescia, Lombardy Region (Italy).
Inclusion criteria were: i) clinical evidence of CNS pro-
gression by radiological imaging; ii) access to follow-up
data; iii) availability of histological blocks of at least the
primary ovarian tumor.
For each case the following clinical and pathological
parameters were collected: i) age at diagnosis; ii) date of
diagnosis of both primary ovarian cancer and CNS me-
tastasis; iii) morphological and histological features of
both ovarian tumor and brain metastasis (histotype and
grade); iv) FIGO stage at diagnosis and residual tumor
after surgery; v) date and site of first relapse; vi) treat-
ments received at diagnosis and relapse; vii) date of
death or last follow-up; viii) overall survival (OS),
counted as the time from the date of EOC diagnosis to
the date of death or last follow-up; ix) progression free
survival (PFS) estimated as the time from EOC diagnosis
to the date of first clinical relapse; x) progression brain
metastasis free survival (bPFS) calculated as the time
from primary tumor diagnosis to brain metastasis devel-
opment; xi) brain metastasis overall survival (bOS) de-
termined as the time from the date of brain metastasis
diagnosis to death or last follow-up. Nineteen new con-
trols, diagnosed from June 2011 to June 2016, without
CNS progression but with similar clinical and histo-
pathological features and follow up were selected from
the clinical records of Candiolo Cancer Institute (FPO-
IRCCS).
The study was submitted to and approved by the Ethic
Institutional Review Board for “Biobanking and use of
human tissues for experimental studies” of the Pathology
Service of the AOU Città della Salute e della Scienza
(Turin, Italy). The project provided a verbal and not
written informed consent from the patients due to the
retrospective approach of the study, which did not im-
pact on their treatment. All the cases were anonymously
recorded. The Institutional Review Board approved this
consent procedure.
Immunohistochemistry procedures
Haematoxylin and eosin (H&E) slides were assessed and
the most representative paraffin block of each lesion was
selected for immunohistochemistry (IHC). A three-
micrometer-thick section was collected on a SuperFrost
Plus slide and, IHC reaction against AR (monoclonal
antibody, clone SP107, pre-diluted in Tris Buffer, pH
7.3–7.7, with 1% BSA and < 0.1% Sodium Azide, Ven-
tana, Roche) was performed on an automated immunos-
tainer (VentanaBenchMark XT AutoStainer, Ventana
Medical Systems, Tucson, AZ, USA). Nuclear staining
was considered positive. Prostate tissue was used as posi-
tive control, while a triple negative basal-like breast can-
cer sample was used as negative control.
Two observers, blinded to clinical data, independently
evaluated staining results, counting the percentage of
positive neoplastic nuclei on 10 high-magnification fields
(400x). At least 100 fields were counted for each sample.
The intensity of nuclear staining was also estimated with
a score ranging from 0 to 3+ (0: absent staining; 1+:
weak nuclear staining; 2+: moderate nuclear staining;
3+: intense nuclear staining). Androgen receptor was
considered as follows: i) continuous variable (ratio of
positive neoplastic cells from 0 to 100%), ii) discrete
variable using cut-off values of 1% [15] and 10% [13, 16],
as previously reported in literature, and iii) dichotomized
variable according to Immunoreactive Score (IRS) [12].
The IRS was obtained by multiplying the intensity of
staining (from 0 to 3+) by the percentage of positive
cells (0 = 0% of stained nuclei; 1 = < 10% of stained nu-
clei; 2 = 10–50% of stained nuclei; 3 = 51–80% of stained
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nuclei; 4 = > 80% of stained nuclei). The samples were
considered positive or negative as follows: score ≤ 2:
negative; score > 2: positive.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware for Windows (version 22.0; SPSS Inc., Chicago, IL).
Categorical variables were initially compared with Pearson
Chi-square test, but when results were not reliable, Fisher
exact test has been considered for further statistical ana-
lyses. Continuous variables were compared using analysis
of variance (ANOVA) or dependent T test for paired sam-
ples. Kaplan-Meier curves were drawn to analyse survival
outcome using the log-rank test method. P values < 0.05
were considered significant, and all tests were two-tailed.
Results
Validation cohort
We collected 29 new cases and 19 new controls as valid-
ation cohort.
Table 1 Clinico-pathological features of primary ovarian lesion in validation cohort: case dataset vs control dataset
Clinico-histopathological features validation cohort Case Dataset
n = 29 (%)
Control Dataset
n = 19 (%)
p Value
Age, median (years) [range] 57 [39–76] 52 [40–78] N.S.
Histological type
Serous 25 (86) 19 (100) N.S.




G3 29 (100) 19 (100) N.S.
FIGO stage
II 2 (7) 0 (0) N.S.
III 19 (65.5) 13 (68)
IV 8 (27.5) 6 (32)
Type of surgery
Upfront 22 (76) 8 (42) 0.02
Neoadjuvant CT + IDS 7 (24) 11 (58)
Macroscopic residual tumor
Present 18 (62) 6 (32) 0.04
Absent 11 (38) 13 (68)
First-line chemotherapy
Platinum-based 29 (100) 19 (100) N.S.
Relapse
Present 29 (100) 12 (63) 0.0004
Absent 7 (37)
First site of relapse
CNS 14 (48) 0 (0) 0.003
Lymph nodes and / or peritoneum 11 (38) 11 (92)a
Other 4 (14) 1 (8)a
Patient’s status
Alive 7 (24) 15 (79) 0.0002
Dead 22 (76) 4 (21)
PFS, median (months) [range] 15 [0–62] 17 [10–62] N.S.
OS, median (months) [range] 48 [4–173] 32 [19–78] N.S.
IDS Interval Debulking Surgery, CT Chemotherapy, CNS Central Nervous System, PFS Progression Free Survival, OS Overall Survival, N.S. not significant
aDisease progression did not occur for 7 patients
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Table 2 Clinical parameters of the 40 CNS metastases included in the study
Cases Age Neurological symptoms N° of lesions Site of lesions Treatment of
CNS metastases
bPFS (months) bOS (months)
Previously Published Cohort
1 49 NA Single Parietal Surgery, CT 11 6
2 57 Drowsiness Single Occipital Surgery 68 42
3 70 Ataxia Single Parietal, occipital Surgery, WBRT 29 41
4 70 Unilateral symptoms Single Parietal Surgery, CT, WBRT 22 6
5 50 Headache, vertigo Double Parietal, occipital, frontal Surgery, CT, WBRT 18 29
6 70 Aphasia, disorientation, dizziness Single Parietal Surgery, SRS 28 56
7 52 NA Single Frontal Surgery, CT, WBRT 54 7
8 62 Headache, altered walking gait Multiple Temporal, frontal, occipital Surgery, WBRT 15 3
9 46 NA Single NA Surgery 23 3
10 72 Ataxia, dysmetria Multiple Frontal (major) Surgery, WBRT 18 7
11 74 Vertigo Single Frontal Surgery, WBRT 25 64
Validation Cohort
12 56 Seizures, aphasia, altered walking gait Single Frontal Surgery, WBRT 0 48
13 77 Persistent vomiting Single Cerebellar Surgery 26 40
14 79 Dysarthria, altered walking gait Single Parietal Surgery 36 6
15 66 Paresthesia, dizziness Multiple Parietal, occipital Surgery, CT, SRS 30 34
16 69 Seizures, dysmetria Single Frontal Surgery 0 12
17 67 Headache, diplopia Single Occipital Surgery, CT 45 12
18 67 Headache, vomit Single Frontal Surgery, WBRT 22 40
19 68 Headache Single Frontal Surgery, WBRT 26 27
20 56 Aphasia, seizures, dysarthria, dysmetria Multiple Temporal, parietal, occipital Surgery, CT, WBRT 61 112
21 57 Headache, vomit Single Cerebellar Surgery, WBRT 18 41
22 60 Altered walking gait Multiple Cerebellar, supratentorial Surgery, CT, WBRT 19 13
23 54 Headache, paresthesia, hemiparesis Multiple Temporal, parietal Surgery, CT, WBRT 15 44
24 46 Altered walking gait Single Cerebellar Surgery, WBRT 25 8
25 69 Altered walking gait, dizziness, Hemianopia Multiple Parietal, occipital Surgery, WBRT 22 39
26 71 Headache Double Frontal, Cerebellar WBRT, CT 32 27
27 51 Aphasia, verbal amnesia Multiple Frontal, temporal, occipital WBRT 34 6
28 59 Headache, altered walking gait Multiple Cerebellar, supratentorial WBRT 25 18
29 74 Altered walking gait, diplopia Multiple Cerebellar, parietal, temporal WBRT 87 17
30 58 Seizures Multiple Cerebellar, supratentorial WBRT 16 22
31 78 NA Multiple supratentorial WBRT 27 2
32 60 NA Double Temporal, frontal WBRT, CT 36 44
33 75 Asthenia, fatigue Multiple Cerebellar, supratentorial WBRT, CT 21 3
34 51 Headache Multiple Parietal, occipital WBRT, CT 72 8
35 54 NA Single Occipital WBRT 1 3
36 49 Hemiparesis Multiple Frontal, temporal, occipital SRS 28 51
37 39 Paresthesia, Dysarthria Multiple Occipital, cerebellar WBRT, CT 4 4
38 55 Drowsiness Multiple Parietal, frontal / 38 2
39 57 Headache, Paresthesia Multiple Frontal, parietal, occipital WBRT, CT 1 15
40 55 Headache Multiple Frontal, cerebellar WBRT, CT 11 9
NA not available, WBRT Whole Brain RadioTherapy, SRS Stereotactic RadioSurgery, CT Chemotherapy, bPFS Progression Brain Metastasis Free Survival, bOS
brain metastases Overall Survival
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Case dataset
Median age at diagnosis was 57 years (range 39–76); the
majority of cases were categorized as serous carcinomas
(25/29, 86%) and all cases were high grade (G3) (29/29,
100%). According to FIGO classification, 2 cases (7%)
were stage II, 19 (65.5%) stage III and 8 (27.5%) stage IV.
Twenty-two out of 29 cases (76%) were treated with
up-front surgery; seven (24%) received neo-adjuvant
chemotherapy (NACT) followed by Interval Debulking
Surgery (IDS). Residual tumor was present in 18 cases
(62%), absent in 11 (38%).
All cases relapsed, with a median PFS of 15 months
(range 0–62). Median age at diagnosis of CNS involve-
ment was 59 years, with a median bPFS of 25 months
(range 0–87 months). Fourteen out of 29 (48%) patients
developed brain metastases as the first site of relapse.
Overall, median bOS was 17months (range 2–112),
while median OS was 48months (range 4–173). At the
time statistical analyses were performed (May 2018), 7/
29 patients (24%) were alive, while 22 (76%) had died.
Table 1 shows the most relevant clinico-pathological
parameters of cases subgroup of the validation cohort.
For more detailed features of CNS involvement in the
combined dataset see Table 2.
Control dataset
The median age of primary EOC diagnosis was 52 years
(range 40–78). All our controls were high grade (G3)
serous carcinomas (19/19, 100%). There were 13 FIGO
stage III (68%) and 6 FIGO stage IV (32%). Eleven out of
19 patients (58%) were treated with neoadjuvant chemo-
therapy followed by IDS. Up-front surgery was chosen
for 8 women (42%), followed by adjuvant chemotherapy.
All patients received platinum-based chemotherapy (19/
19, 100). Thirteen patients (68%) had no residual tumor
after surgery. Twelve controls (63%) experienced at least
one relapse of the disease. Median PFS was 17months
(range 10–62), whereas median OS was 32months
(range 19–78). When data were processed, 4 (21%) pa-
tients had died.
Table 1 shows the most relevant clinico-pathological
parameters of control subgroup.
Cases and controls of the validation cohort were com-
parable: no statistical difference was observed for age,
histotype, tumor grade, FIGO stage, and first line
chemotherapy (see Table 1). Significant differences be-
tween two group were observed for upfront surgery vs
interval cytoreductive surgery, absence/presence of re-
sidual tumor after surgery, incidence of relapse and
number of surviving patients.
AR expression in cases and controls of the validation cohort
Immune-histochemical stainings were performed on
both cases and controls of the validation cohort. Table 3
shows comparisons between cases vs controls, consid-
ered as continuous variables.
For AR protein expression in cases and controls of the
validation cohort as dichotomized variable see Table 4.
AR expression is significantly reduced in cases vs
controls’ validation cohort
Case dataset vs. control dataset
AR shows a statistically significant difference between
the subgroups when considered as continuous variable
(mean case dataset: 13.21%; mean control dataset:
43.21%, p < 0.001, see Table 3).
Table 3 Immune-histochemical results and statistical analyses of AR considered as continuous variable: comparisons of cases vs
controls in validation cohort
IHC parameter Cases vs controls
(%)
N Mean (%) Median (%) Range p Value
AR Cases 29 13.21 5 0–70 < 0.001
Controls 19 43.21 40 1–95
AR Androgen Receptor
Table 4 Immune-histochemical results and statistical analyses of AR considered as dichotomized variable as for both cases and
controls validation datasets




p Value (Cases vs controls:
IHC comparison)
OR (Cases vs controls)
(CI 95%)
AR < 1% 4/29 (13.8) 0/19 (0) 0.142
≥ 1% 25/29 (86.2) 19/19 (100)
< 10% 20/29 (69) 4/19 (21.1) 0.003 8,33 (2.15–32.29)
≥ 10% 9/29 (31) 15/19 (78.9)
IRS≤ 2 24/29 (82.8) 4/19 (21.1) < 0.001
IRS > 2 5/29 (17.2) 15/19 (78.9)
AR Androgen Receptor
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Moreover, considered as dichotomized variable, differ-
ent expression of AR among the two populations
emerges (p = 0.003 for10% cut-off and p < 0.001 for
IRS). Thus, odds-ratio (OR) was evaluated for 10% AR’s
cut-off and the risk to develop a brain metastasis was 8,
33 times higher in women with AR-negative primary
EOCs (CI 95%: 2.15–32.29). (See Table 4).
Combined analysis
We analyzed the combined dataset including previous
published cohort and new validation cohort, for a total
of 40 cases and 40 controls.
Case dataset
Median age at diagnosis was 57 years (range 39–76); 34/
40 cases were categorized as serous carcinomas (85%) and
all cases were considered as high grade (G3) tumors (40/
40, 100%). As for FIGO classification, 4 cases (10%) were
stage II, 25 (62.5%) stage III and 11 (27.5%) stage IV.
Most of our cases (31/40, 77.5%) were treated with up-
front surgery; nine (22.5%) received neo-adjuvant
chemotherapy (NACT) followed by Interval Debulking
Surgery (IDS). Each case received a platinum-based
chemotherapy, with Carboplatin alone (2/40, 5%) or in
combination with paclitaxel, (38/40, 95%). Residual
tumor was present in 17 cases (42.5%), absent in 14
(22.5%), unknown for 9 patients (22.5%).
All cases relapsed, with a median PFS of 18 months
(range 0–62). Median age at diagnosis of CNS involve-
ment was 59.5 years, with a median bPFS of 25 months
(range 0–87 months). Twenty one out of 40 (52.5%) pa-
tients developed brain metastases as the first site of re-
lapse. Further sites of first relapse were lymph nodes
and/or peritoneum (14/40, 35%) lung or liver (5/40,
12.5%).
Overall, median bOS was 12months (range 2–112),
while median OS was 47.5 months (range 4–173). When
statistical analyses were performed (May 2018), 10/40
patients (25%) were alive, whilst 29 (72.5%) had died;
vital status data was not available for one patient (2.5%).
Table 5 shows the most relevant clinico-pathological
parameters of case subgroup.
For more details about features of CNS involving see
Table 2.
Control dataset
This group included 40 women with a median age of
primary EOC diagnosis of 63.5 years (range 36–78). All
of our controls were identified as high grade (G3) serous
carcinomas (40/40, 100%). There were 4 FIGO stage II
(10%), 25 FIGO stage III (62.5%) and 11 FIGO stage IV
(27.5%). Most patients (22/40, 55%) were treated with
neoadjuvant chemotherapy (Carboplatin alone, 1/22
4.5%, Carboplatin and paclitaxel, 19/22 86.4%,
Table 5 Clinico-pathological features of primary ovarian lesion





n = 40 (%)
Control
Dataset








Serous 34 (85) 40 (100) 0.262






G3 40 (100) 40 (100) 1
FIGO stage
II 4 (10) 4 (10) 1
III 25 (62.5) 25 (62.5)
IV 11 (27.5) 11 (27.5)
Type of surgery
Upfront 31 (77.5) 18 (45) 0.003
Neoadjuvant CT + IDS 9 (22.5) 22 (55)
Macroscopic residual tumor
Present 17 (42.5) 19 (47.5) 0.611
Absent 14 (35) 20 (50)
Not available 9 (22.5) 1 (2.5)
First-line chemotherapy
Platinum-based 40 (100) 40 (100) 1
Relapse
Present 40 (100) 30 (75) 0.001
Absent 10 (25)
First site of relapse
CNS 21 (52.5) < 0.001
Lymph nodes and / or
peritoneum
14 (35) 28 (93.3)a
Other 5 (12.5) 2 (6.7)a
Patient’s status
Alive 10 (25) 21 (52.5) 0.015
Dead 29 (72.5) 19 (47.5)
Not available 1 (2.5)
PFS, median (months) [range] 18 [0–62] 17.5 [5–73]
OS, median (months) [range] 47.5 [4–
173]
40 [6–101]
IDS Interval Debulking Surgery, CT Chemotherapy, CNS Central Nervous
System, PFS Progression Free Survival, OS Overall Survival
aDisease progression did not occur for 10 patients
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Carboplatin, paclitaxel and Bevacizumab, 2/22 9.1%)
followed by IDS. Up-front surgery was chosen for the
remaining 18 women, followed by adjuvant chemother-
apy (Carboplatin plus paclitaxel, 13/18 72.2% Carbopla-
tin, paclitaxel and Bevacizumab, 3/18 16.7%, Carboplatin
and Pegylated Liposomal Doxorubicin 1/18 5.6%, Carbopla-
tin, Pegylated Liposomal Doxorubicin and Bevacizumab, 1/
18 5.6%). Nineteen patients (47.5%) had residual tumor
after surgery; for one patient (1/40, 2.5%) this datum was
not retrievable. Thirty out of 40 controls (75%) experienced
at least one relapse of the disease, whose first localization
involved either lymph nodes and/or peritoneum (28/30,
93.3%) or liver (2/30, 6.7%). Median PFS was 17.5months
(range 5–73), whereas median OS was 40months (range
6–101). When data were processed, 19 (47.5%) patients had
died.
Table 5 shows the most relevant clinico-pathological
parameters of control subgroup of combined dataset.
Cases and Controls proved to be comparable popula-
tions: no statistical difference was observed for age (p =
0.960), histotype (p = 0.262), tumor grade (p = 1), FIGO
stage (p = 1), residual tumor after surgery (p = 0.611) and
first line chemotherapy (p = 1) (Table 5). There were sig-
nificant differences between cases and controls, in par-
ticular upfront surgery vs interval cytoreductive surgery,
incidence of relapse and number of surviving patients.
For AR protein expression of combined cohort as con-
tinuous variable of primary vs metastatic lesions and of
cases vs controls see Table 6. AR expression in cases
and controls dataset of combined cohort considered as
dichotomized variable is showed in Table 7.
AR expression is significantly reduced in cases vs
controls’ combined cohort
Case dataset vs. control dataset
AR shows a statistically significant difference between
cases and controls when considered as continuous vari-
able (mean case dataset: 14.15%; mean control dataset:
42.05%, p < 0.001, Table 6).
Considered as dichotomized variable, the two populations
showed different expression of AR (p < 0.001 for both 10%
cut-off and IRS). Odds-ratio (OR) evaluated for 10% AR’s
cut-off was 9.43 (CI 95%: 3.290–27.020) (See Table 7).
Figure 1 shows the immune-histochemical expression
of AR with the corresponding H&E staining in two rep-
resentative cases and two controls.
AR expression is not differentially expressed in primary
ovarian cancers vs paired brain metastases
Primary ovarian cancers vs paired brain metastases
IHC expression of AR doesn’t exhibit statically significant
difference of expression between the two groups in the
combined population, considering continuous variable only
(See Table 6).
Kaplan-Meier’s curves of combined population
Survival curves were obtained using PFS (progression free
survival) and bPFS (progression brain metastasis free sur-
vival) as events of interest in the combined population. AR
results associated with prognosis in this population as show
the Kaplan-Meier’s (KM) curves, in particular: KM curve by
AR 10% and PFS (Fig. 2, curve a, p = 0.002) and KM curve
by AR 10% and bPFS (Fig. 2, curve b, p = 0.005).
Table 6 Immune-histochemical results and statistical analyses of AR considered as continuous variable: comparisons of both cases
vs controls and primary vs metastatic lesions
IHC parameter Cases vs controls // primary vs metastatic lesions (%) N Mean (%) Median (%) Range p Value
AR Cases 39 14.15 5 0–70 < 0.001
Controls 40 42.05 37.5 0–95
Primary tumor 24 12.70 2.5 0–70 0.270
Brain metastasis 24 9.25 0 0–60
AR Androgen Receptor
Table 7 Immune-histochemical results and statistical analyses of AR considered as dichotomized variable as for both cases and
controls datasets




p Value (Cases vs controls:
IHC comparison)
OR (Cases vs controls)
(CI 95%)
AR < 1% 7/39 (17.9) 2/40 (5) 0.087
≥ 1% 32/39 (82.1) 38/40 (95)
< 10% 26/39 (66.7) 7/40 (17.5) < 0.001 9.429 (3.290–27.020)
≥ 10% 13/39 (33.3) 33/40 (82.5)
IRS≤ 2 31/39 (79.5) 13/40 (32.5) < 0.001
IRS > 2 8/39 (20.5) 27/40 (67.5)
AR Androgen Receptor
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Discussion
Little evidence from small series of patients exists about
predictors of CNS involvement from EOC. Few clinical and
molecular factors have been studied, such as CD133 over-
expression and platinum resistance [17], overexpression of
MDR-1 (multi drug resistance 1) [18], having suffered from
a previous breast cancer [19], loss of BRCA function [20]
and, presence of mutations in BRCA1 and BRCA2 genes
[21]. In our work we explored the predictive and prognostic
role of AR.
Fig. 1 a (5x) c (20x): H&E staining in ovarian serous carcinoma metastatic to the brain with the corresponding negative AR immunoreaction (b,
5x) and focal and weak AR expression (d, 20x) in primary tumor cells. e (5x), g (20x): H&E staining in control cases of ovarian carcinoma with
strong and diffuse AR expression (f, h: 5x and 20x respectively)
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The main conclusion of the current study is that de-
creased AR levels predict CNS involvement from EOC.
In an independent validation cohort, we showed a 8,33
times higher risk of disease’s spreading to CNS if AR’s
amount on primary tumor is lower than 10%, statistically
significant both for AR considered as dichotomized or
continuous variable (see Table 4). Moreover, in our
complete dataset, including cases and controls of previ-
ous work [14], we confirmed these data, with AR expres-
sion significant reduction in cases vs controls (see
Tables 6 and 7) and a more than 9 times greater risk of
developing brain metastases if AR showed less than 10%
of expression (see Table 7).
In combined dataset AR levels also have a prognostic
value, as reported in KM curve (Fig. 2, curve a). Indeed,
a reduced AR, is associated with shorter PFS, regardless
of site relapse.
Our data are consistent with other studies performed
in EOC [16, 22, 23] breast [24, 25] and endometrial can-
cer [26] that suggest a positive prognostic role of AR
expression.
Most importantly we show for the first time that be-
sides causing earlier involvement of any other site, AR
loss also has a negative prognostic relevance if bPFS is
considered: lower AR levels correlate with an earlier
CNS spreading (Fig. 2, Curve b).
Moreover, we also first compare AR expression in pri-
mary and paired CNS metastatic site (See Table 6).
Data on this topic are limited [27, 28]. When this re-
ceptor is considered as continuous variable, no differ-
ence of expression is observed between ovarian and
brain lesions, differently from the previous study [14]
(see Table 6); it is clear that a correlation to de-
differentiation exists, since metastatic lesions disclose
lower percentages of the evaluated protein compared
with primary ovarian tumors.
It is worthwhile mentioning that 21 cases (52.5%) of
the combined population had the CNS as the first site of
relapse. Such tendency may be explained with the im-
provement of chemotherapeutic agents, able to contrast
typical routes of metastatic spread, though unable to
cross the blood-brain barrier (BBB) [29].
Our study has some limitations. First, sample size was
increased, but is still relatively small. Second, BRCA mu-
tational status was known only in 4/40 (10%) of cases (3
were mutated, one was not). This lack of information
may be important since BRCA mutation is a known in-
dependent positive predictive and prognostic factor [30].
Third, in 22.5% of patients residual disease after surgery
is unknown. This is a limit because macroscopic residual
tumor after surgery is an independent prognostic factor
in ovarian cancer [31], although it is unlikely to impact
specifically on the development of brain metastases.
Fourth, nearly all patients in our study have serous can-
cers, a good prognostic factor for patients with CNS in-
volvement [11]. We could have selected a population
with better prognosis, but in any case it appears to be
well balanced to the control group as regards histology
(see Table 5).
In conclusion, we confirmed in an independent valid-
ation cohort that AR reduction is predictive of CNS in-
volvement from EOC. Assessment of AR levels might
help in the identification of high risk patients who may
benefit from dedicated follow up procedures to antici-
pate diagnosis and treatment.
However, before applying this biomarker to clinical
practice, further evidence on larger series of EOC pa-
tients is needed.
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